On March 9, 2022 Pimera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing breakthrough medicines for cancer and other diseases with high unmet medical need, reported that an oral presentation on PMR-116 will be delivered at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, being held in New Orleans, LA, April 8-13, 2022 (Press release, Pimera Therapeutics, MAR 9, 2022, View Source [SID1234609831]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the oral presentation are as follows:

Title: "PMR-116, a novel inhibitor of ribosome biogenesis with antitumor activity in preclinical models of prostate cancer"
Date and Time: April 11, 2022, 3:05 PM-3:20 PM

Location: Great Hall AD, New Orleans Convention Center

About PMR-116

PMR-116 is our lead therapeutic in clinical development for multiple cancer indications including solid tumors. PMR-116 acts through a novel mechanism of action, targeting the RNA polymerase I, or POL I, a transcription factor for MYC driven cancers and other diseases with high unmet medical need. In preclinical studies, PMR-116 has demonstrated robust preclinical efficacy in multiple MYC-driven models, including those that are resistant to standard-of-care treatments. PMR-116 is currently in the dose escalation stage of a Phase 1a/b clinical trial being conducted in Australia. Pimera intends to expand the development of PMR-116 in patients with MYC overexpressing solid tumors in a tumor type-agnostic approach. For more information about the ongoing clinical trial, please visit ANZCTR.